BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis

Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $7.48 to $7.71
• 50-Day Range: $7.38 to $9.39
• 52-Week Range: $4.03 to $9.50
• Volume: 329,797 shs
• Average Volume: 2.78 million shs
• Market Capitalization: $1.60 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.57
• Consensus Rating: Moderate Buy

BioCryst Pharmaceuticals Stock Analysis - MarketRank™

BioCryst Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 152nd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

BioCryst Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.36) to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioCryst Pharmaceuticals is -12.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioCryst Pharmaceuticals is -12.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.03% of the float of BioCryst Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

BioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in BioCryst Pharmaceuticals has recently increased by 23.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioCryst Pharmaceuticals does not currently pay a dividend.

Dividend Growth

BioCryst Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.85

Percentage of Shares Shorted

10.03% of the float of BioCryst Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

BioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in BioCryst Pharmaceuticals has recently increased by 23.49%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.19

News Sentiment

BioCryst Pharmaceuticals has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for BioCryst Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 5 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

MarketBeat Follows

2 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.80% of the stock of BioCryst Pharmaceuticals is held by insiders.

Percentage Held by Institutions

85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BCRX Stock Analysis - Frequently Asked Questions

How have BCRX shares performed this year?

BioCryst Pharmaceuticals' stock was trading at $7.52 at the beginning of the year. Since then, BCRX shares have increased by 4.5% and is now trading at $7.86.
View the best growth stocks for 2025 here.

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its quarterly earnings results on Monday, February, 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.06. BioCryst Pharmaceuticals's quarterly revenue was up 40.8% on a year-over-year basis.

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' top institutional shareholders include Vanguard Group Inc. (10.57%), Deerfield Management Company L.P. Series C (3.93%), Geode Capital Management LLC (2.33%) and Nuveen Asset Management LLC (1.65%). Insiders that own company stock include Jon P Stonehouse, Yarlagadda S Babu, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders, Michael L Jones and Steve Aselage.
View institutional ownership trends.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioCryst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Pfizer (PFE) and PayPal (PYPL).

Company Calendar

• Last Earnings: 2/24/2025
• Today: 3/31/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BCRX
• CIK: 882796
• Web: www.biocryst.com
• Phone: (919) 859-1302
• Fax: 919-859-1314
• Employees: 530
• Year Founded: 1986

Price Target and Rating

• Average Stock Price Target: $15.57
• High Stock Price Target: $30.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +98.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-226,540,000.00
• Net Margins: -30.01%
• Pretax Margin: -30.08%
• Return on Equity: N/A
• Return on Assets: -24.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.78
• Quick Ratio: 2.73

Sales & Book Value

• Annual Sales: $450.71 million
• Price / Sales: 3.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.22) per share
• Price / Book: -3.54

Miscellaneous

• Outstanding Shares: 208,960,000
• Free Float: 197,191,000
• Market Cap: $1.64 billion
• Optionable: Optionable
• Beta: 1.85